Genenta Science S.p.A.
GNTA$16M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaMILAN13 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
15wMarket Overview
Stock performance and key metrics
GNTA News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab | Phase 2 | Clear Cell RCC | - | - |
Temferon | Phase 2 | Glioblastoma Multiforme | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply